After left atrial appendage (LAA) occlusion with the Watchman device (Boston Scientific), an antithrombotic strategy centered on a half-dose of a direct oral anticoagulant (DOAC) may improve outcomes ...

The risk for death goes up for patients with atrial fibrillation (AF) who are put on direct oral anticoagulants (DOAC) at dosages other than those approved for stroke prevention, whether higher or ...

ORLANDO, Florida — Combining aspirin and direct oral anticoagulant (DOAC) therapy for the secondary prevention of venous thromboembolism (VTE) or the prevention of stroke associated with nonvalvular ...

In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...

Study authors assessed the effectiveness and safety of DOACs compared with warfarin in patients with valvular atrial fibrillation. People with valvular atrial fibrillation (AF) who are new users of ...

Swedish cohort study shows 13% (95% CI, 2-22%) lower risk of kidney function decline or kidney failure and 12% (95% CI, 3-20%) lower risk of acute kidney injury with use of direct oral anticoagulants ...

The DOAC Dipstick (DOASENSE GmbH) is a single-use, point-of-care dipstick test that is used to detect direct oral anticoagulants (DOACs) in urine. The urine dipstick test detects DOACs (both factor Xa ...

In 2017, we have the advantage of, having available to us, 4 large clinical trials. All of the phase IV studies that have been published over the last few years review the use of novel oral ...

The direct oral anticoagulants edoxaban, apixaban, rivaroxaban and dabigatran have been recently approved for the treatment of non-valvular atrial fibrillation The new direct oral anticoagulants ...

In a recent study published in JAMA Network Open, researchers compared outcomes related to three direct oral anticoagulant (DOAC) care models to prevent anticoagulation-associated adverse effects ...

FREMONT, Calif., March 22, 2026 (GLOBE NEWSWIRE)-- CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today ...